Released Mar 24, 2022, before the open
10-K filed Mar 24, 2022, 83 days after period end · 0001785530-22-000014
Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$17.87M-$17.87M derivedN/M vs Q4 2020N/M vs Q3 2021
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$17,884,000N/M
Operating Cash Flowderived-$12,673,000N/M
Free Cash Flowderived-$12,945,000N/M
What the release said
The release
Same quarter
| Metric | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures |
|---|---|---|
| Net Income | -$17.87M | -$7.40M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR